Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 307

1.

Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores.

Ademuyiwa FO, Thorat MA, Jain RK, Nakshatri H, Badve S.

Mod Pathol. 2010 Feb;23(2):270-5. doi: 10.1038/modpathol.2009.172. Epub 2009 Nov 27.

2.

Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.

Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, Lunet N, Schmitt F.

Breast Cancer Res. 2009;11(3):R40. doi: 10.1186/bcr2327. Epub 2009 Jun 23.

3.

Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.

Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S.

J Clin Pathol. 2008 Mar;61(3):327-32. Epub 2007 Nov 23.

PMID:
18037662
4.

Histopathologic variables predict Oncotype DX recurrence score.

Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R.

Mod Pathol. 2008 Oct;21(10):1255-61. doi: 10.1038/modpathol.2008.54.

5.

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI.

Am J Surg. 2008 Oct;196(4):527-9. doi: 10.1016/j.amjsurg.2008.06.021.

PMID:
18809056
6.

Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.

Yorozuya K, Takeuchi T, Yoshida M, Mouri Y, Kousaka J, Fujii K, Nakano S, Fukutomi T, Hara K, Ichihara S, Lin Y, Kikuchi S.

J Cancer Res Clin Oncol. 2010 Jun;136(6):939-44. doi: 10.1007/s00432-009-0736-8. Epub 2009 Nov 28.

PMID:
19946706
7.
8.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

9.
10.

Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.

Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO.

Eur J Cancer. 2008 Jul;44(11):1541-51. doi: 10.1016/j.ejca.2008.04.020. Epub 2008 Jun 4.

PMID:
18538561
11.

Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.

Ijichi N, Shigekawa T, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S.

Horm Cancer. 2012 Aug;3(4):147-59. doi: 10.1007/s12672-012-0111-0. Epub 2012 Apr 3.

PMID:
22476979
12.

Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.

Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, Aishima S, Morita M, Kakeji Y, Maehara Y.

Ann Surg Oncol. 2012 Apr;19(4):1145-52. doi: 10.1245/s10434-011-2094-4. Epub 2011 Oct 8.

PMID:
21984487
13.

The significance of GATA3 expression in breast cancer: a 10-year follow-up study.

Ciocca V, Daskalakis C, Ciocca RM, Ruiz-Orrico A, Palazzo JP.

Hum Pathol. 2009 Apr;40(4):489-95. doi: 10.1016/j.humpath.2008.09.010. Epub 2008 Dec 11.

PMID:
19084267
14.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
15.

LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.

Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.

Anticancer Res. 2004 Jul-Aug;24(4):2391-400.

16.

Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.

Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG, Shak S.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8623-31.

17.

FOXA1 is an independent prognostic marker for ER-positive breast cancer.

Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S.

Breast Cancer Res Treat. 2012 Feb;131(3):881-90. doi: 10.1007/s10549-011-1482-6. Epub 2011 Apr 19.

PMID:
21503684
18.

Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?

Milburn M, Rosman M, Mylander C, Tafra L.

Breast J. 2013 Jul-Aug;19(4):357-64. doi: 10.1111/tbj.12126. Epub 2013 May 23.

PMID:
23701403
19.

Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.

Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG.

Cancer Res. 2005 Dec 15;65(24):11259-64.

20.

Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.

Biroschak JR, Schwartz GF, Palazzo JP, Toll AD, Brill KL, Jaslow RJ, Lee SY.

Breast J. 2013 May-Jun;19(3):269-75. doi: 10.1111/tbj.12099.

PMID:
23614365

Supplemental Content

Support Center